Physician profile

Jocel Pagan-Ferrer

General Practice · Carolina, PR

NPI 1508178104

$851.42

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$261.65

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Janssen Pharmaceuticals, INC $313.16 2019-2022
Abbott Laboratories $149.99 2024 Merlin@Home
Teva Pharmaceuticals USA, INC. $112.50 2020
Amgen INC. $99.60 2022
E.R. Squibb & Sons, L.L.C. $69.58 2024 Eliquis
Merck Sharp & Dohme LLC $49.19 2021-2023 Zerbaxa, Recarbrio
Smith+Nephew, INC. $24.71 2024 Pico 7, Iodoflex Dressing 5x5g USA
Edwards Lifesciences Corporation $19.18 2019
Chiesi USA, INC. $13.51 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jocel Pagan-Ferrer

$851.42

in general payments reported 2019-2025

Years
2019-2024
Top company
Janssen Pharmaceuticals, INC

https://glasscript.com/doctor/23129/jocel-pagan-ferrer

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.